Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 11 | 2018 | 65 | 1.170 |
Why?
|
| Visual Acuity | 12 | 2018 | 73 | 1.050 |
Why?
|
| Lens Subluxation | 3 | 2006 | 4 | 0.730 |
Why?
|
| Macular Edema | 7 | 2018 | 17 | 0.720 |
Why?
|
| Vitreous Body | 4 | 2011 | 10 | 0.550 |
Why?
|
| Eye Injuries | 2 | 2006 | 16 | 0.470 |
Why?
|
| Cataract Extraction | 4 | 2014 | 11 | 0.460 |
Why?
|
| Eye Infections, Fungal | 1 | 2013 | 1 | 0.440 |
Why?
|
| Candida albicans | 1 | 2013 | 12 | 0.440 |
Why?
|
| Endophthalmitis | 1 | 2013 | 8 | 0.430 |
Why?
|
| Scleral Buckling | 1 | 2011 | 3 | 0.390 |
Why?
|
| Eye Diseases | 1 | 2011 | 5 | 0.390 |
Why?
|
| Foreign-Body Migration | 1 | 2011 | 10 | 0.390 |
Why?
|
| Sutures | 1 | 2011 | 20 | 0.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2017 | 1428 | 0.380 |
Why?
|
| Suture Techniques | 1 | 2011 | 61 | 0.370 |
Why?
|
| Macular Degeneration | 1 | 2009 | 22 | 0.330 |
Why?
|
| Methotrexate | 1 | 2009 | 64 | 0.330 |
Why?
|
| Laser Coagulation | 4 | 2018 | 13 | 0.310 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 240 | 0.300 |
Why?
|
| Hypoglycemic Agents | 3 | 2017 | 181 | 0.300 |
Why?
|
| Retinal Diseases | 2 | 2006 | 20 | 0.280 |
Why?
|
| Play and Playthings | 1 | 2006 | 8 | 0.270 |
Why?
|
| Retinal Vein Occlusion | 1 | 2005 | 1 | 0.260 |
Why?
|
| Nematode Infections | 1 | 2005 | 2 | 0.260 |
Why?
|
| Eye Infections, Parasitic | 1 | 2005 | 2 | 0.260 |
Why?
|
| Vision Disorders | 1 | 2004 | 23 | 0.240 |
Why?
|
| Vitrectomy | 1 | 2004 | 9 | 0.240 |
Why?
|
| Thiazolidinediones | 2 | 2017 | 47 | 0.240 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2018 | 36 | 0.220 |
Why?
|
| Lens, Crystalline | 1 | 2002 | 2 | 0.210 |
Why?
|
| Cataract | 1 | 2002 | 8 | 0.210 |
Why?
|
| Humans | 22 | 2018 | 32114 | 0.210 |
Why?
|
| Contusions | 1 | 2002 | 41 | 0.210 |
Why?
|
| Male | 15 | 2018 | 19217 | 0.190 |
Why?
|
| Postoperative Complications | 1 | 2004 | 780 | 0.160 |
Why?
|
| Fluocinolone Acetonide | 1 | 2018 | 5 | 0.160 |
Why?
|
| Female | 13 | 2018 | 20015 | 0.150 |
Why?
|
| Middle Aged | 12 | 2018 | 11839 | 0.140 |
Why?
|
| Prognosis | 4 | 2014 | 1497 | 0.140 |
Why?
|
| Hyperglycemia | 2 | 2014 | 84 | 0.140 |
Why?
|
| Aged | 8 | 2014 | 10314 | 0.130 |
Why?
|
| Diabetic Angiopathies | 2 | 2014 | 143 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 2265 | 0.130 |
Why?
|
| Lasers, Dye | 1 | 2013 | 1 | 0.120 |
Why?
|
| Triamcinolone Acetonide | 1 | 2013 | 4 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2010 | 3510 | 0.110 |
Why?
|
| Photography | 1 | 2013 | 44 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2013 | 40 | 0.110 |
Why?
|
| Infant, Premature | 1 | 2013 | 69 | 0.110 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 224 | 0.100 |
Why?
|
| Adult | 5 | 2006 | 9380 | 0.100 |
Why?
|
| Fluorescein Angiography | 2 | 2009 | 16 | 0.100 |
Why?
|
| Injections | 2 | 2009 | 64 | 0.100 |
Why?
|
| Tomography, Optical Coherence | 2 | 2009 | 45 | 0.100 |
Why?
|
| Cardiovascular Diseases | 3 | 2014 | 1128 | 0.100 |
Why?
|
| Retinal Detachment | 1 | 2011 | 9 | 0.100 |
Why?
|
| Penicillin G Benzathine | 1 | 2011 | 1 | 0.100 |
Why?
|
| Choroid Diseases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Granuloma | 1 | 2011 | 14 | 0.100 |
Why?
|
| Syphilis | 1 | 2011 | 10 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2013 | 672 | 0.090 |
Why?
|
| Choroid Neoplasms | 1 | 2010 | 3 | 0.090 |
Why?
|
| Iodine Radioisotopes | 1 | 2010 | 16 | 0.090 |
Why?
|
| Brachytherapy | 1 | 2010 | 24 | 0.090 |
Why?
|
| Exudates and Transudates | 1 | 2009 | 2 | 0.090 |
Why?
|
| Infant | 1 | 2013 | 1062 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2009 | 38 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 3990 | 0.080 |
Why?
|
| Melanoma | 1 | 2010 | 164 | 0.080 |
Why?
|
| Glucocorticoids | 3 | 2018 | 146 | 0.080 |
Why?
|
| Disease Progression | 3 | 2017 | 594 | 0.080 |
Why?
|
| Child | 2 | 2006 | 2442 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 352 | 0.070 |
Why?
|
| Incidence | 3 | 2017 | 1199 | 0.070 |
Why?
|
| Retinal Vessels | 1 | 2006 | 19 | 0.070 |
Why?
|
| Retina | 2 | 2007 | 61 | 0.070 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2006 | 2 | 0.070 |
Why?
|
| Rupture | 1 | 2006 | 34 | 0.070 |
Why?
|
| Consumer Product Safety | 1 | 2006 | 2 | 0.070 |
Why?
|
| Blindness | 1 | 2006 | 10 | 0.070 |
Why?
|
| Adolescent | 2 | 2006 | 3568 | 0.070 |
Why?
|
| Product Labeling | 1 | 2006 | 16 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 56 | 0.070 |
Why?
|
| Nematoda | 1 | 2005 | 2 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 246 | 0.060 |
Why?
|
| Papilledema | 1 | 2005 | 13 | 0.060 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2014 | 8 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 560 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 401 | 0.050 |
Why?
|
| Risk Factors | 2 | 2014 | 3880 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2017 | 525 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 881 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 1542 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 770 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 494 | 0.030 |
Why?
|
| Decision Trees | 1 | 2014 | 31 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 164 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 2013 | 11 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1817 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 105 | 0.030 |
Why?
|
| Animals | 1 | 2005 | 7542 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 582 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 3306 | 0.020 |
Why?
|
| Simvastatin | 1 | 2010 | 25 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2010 | 4 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 58 | 0.020 |
Why?
|
| Ligands | 1 | 2010 | 81 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 101 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2010 | 53 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 288 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2010 | 173 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 317 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 517 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 236 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 464 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 472 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 324 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 112 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2007 | 548 | 0.020 |
Why?
|
| Research Design | 1 | 2007 | 315 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 510 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 2151 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 960 | 0.010 |
Why?
|